VERV Stock Forecast 2025-2026
Distance to VERV Price Targets
VERV Price Momentum
10 Quality Stocks Worth Considering Now
Researching Verve (VERV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VERV and similar high-potential opportunities.
Latest VERV Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, VERV has a bullish consensus with a median price target of $21.00 (ranging from $15.00 to $32.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $5.97, the median forecast implies a 251.8% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Whitney Ijem at Canaccord Genuity, projecting a 436.0% upside. Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 151.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VERV Analyst Ratings
VERV Price Target Range
Latest VERV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VERV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $15.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $15.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $14.00 |
| Nov 6, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $17.00 |
| Nov 6, 2024 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $32.00 |
| Aug 12, 2024 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $29.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $15.00 |
| Aug 9, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $20.00 |
| May 9, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $15.00 |
| Apr 3, 2024 | Stifel | Dae Gon Ha | Buy | Maintains | $40.00 |
| Feb 28, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $35.00 |
| Sep 13, 2023 | Cantor Fitzgerald | Rick Bienkowski | Neutral | Reiterates | $22.00 |
| Aug 29, 2023 | Cantor Fitzgerald | Rick Bienkowski | Neutral | Reiterates | $22.00 |
| Aug 15, 2023 | Guggenheim | Seamus Fernandez | Buy | Maintains | $55.00 |
| Aug 11, 2023 | Credit Suisse | Richard Law | Neutral | Reiterates | $31.00 |
| Jun 16, 2023 | Canaccord Genuity | Whitney Ijem | Buy | Reiterates | $29.00 |
| May 16, 2023 | RBC Capital | Luca Issi | Outperform | Reiterates | $35.00 |
| Apr 13, 2023 | Canaccord Genuity | Whitney Ijem | Buy | Initiates | $29.00 |
| Feb 1, 2023 | Cantor Fitzgerald | Rick Bienkowski | Neutral | Initiates | $21.00 |
| Dec 15, 2022 | Goldman Sachs | Andrea Tan | Sell | Initiates | $13.00 |
Verve Therapeutics Inc. (VERV) Competitors
The following stocks are similar to Verve based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Verve Therapeutics Inc. (VERV) Financial Data
Verve Therapeutics Inc. has a market capitalization of $530.11M with a P/E ratio of 0.0x. The company generates $32.33M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +154.3% quarter-over-quarter, while maintaining an operating margin of -428.6% and return on equity of -36.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Verve Therapeutics Inc. (VERV) Business Model
About Verve Therapeutics Inc.
Develops gene-editing therapies for cardiovascular diseases.
The company generates revenue by developing advanced gene-editing therapies that address the root causes of cardiovascular diseases. Their innovative approach focuses on creating single-course treatments that provide lifelong benefits, setting them apart from traditional therapies that require ongoing administration.
Located in Cambridge, Massachusetts, Verve Therapeutics collaborates with top academics and industry experts to enhance medical research and advance genomic medicine, positioning itself as a leader in the biotech field.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
274
CEO
Dr. Sekar Kathiresan M.D.
Country
United States
IPO Year
2021
Website
www.vervetx.comVerve Therapeutics Inc. (VERV) Latest News & Analysis
Verve Therapeutics granted equity awards to four new employees under its 2024 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics expanding its workforce with equity awards signals growth potential, which could enhance innovation and attract talent, impacting future stock performance positively.
Initial data from the Heart-2 Phase 1b trial for VERVE-102, targeting PCSK9, is expected in Q2 2025, with final dose escalation data anticipated in H2 2025.
The timeline for VERVE-102's clinical trial results may impact investor sentiment, influencing stock performance and potential market opportunities in the biotech sector.
Verve Therapeutics (VERV) reported a quarterly loss of $0.58 per share, beating the Zacks Consensus Estimate of $0.72 and improving from a loss of $0.69 per share a year prior.
Verve Therapeutics' smaller-than-expected loss indicates improved operational efficiency, potentially boosting investor confidence and affecting stock performance positively.
Kuehn Law is investigating potential fiduciary duty breaches by Verve Therapeutics' officers and directors related to possible self-dealing.
Concerns over potential self-dealing and fiduciary breaches at Verve Therapeutics could lead to legal issues, affecting the company's reputation and stock performance.
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
1 month agoVerve Therapeutics CEO Sekar Kathiresan will speak at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, discussing advancements in genetic medicines for cardiovascular disease.
Verve Therapeutics' participation in a prominent biotech conference highlights its visibility and potential in the market, which may influence investor sentiment and stock performance.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Verve Therapeutics investors who bought shares before August 9, 2022. For details, visit bgandg.com/VERV.
The investigation into Verve Therapeutics may indicate potential legal or regulatory issues, impacting stock performance and investor sentiment for those holding or considering the stock.
Frequently Asked Questions About VERV Stock
What is Verve Therapeutics Inc.'s (VERV) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Verve Therapeutics Inc. (VERV) has a median price target of $21.00. The highest price target is $32.00 and the lowest is $15.00.
Is VERV stock a good investment in 2025?
According to current analyst ratings, VERV has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VERV stock?
Wall Street analysts predict VERV stock could reach $21.00 in the next 12 months. This represents a 251.8% increase from the current price of $5.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Verve Therapeutics Inc.'s business model?
The company generates revenue by developing advanced gene-editing therapies that address the root causes of cardiovascular diseases. Their innovative approach focuses on creating single-course treatments that provide lifelong benefits, setting them apart from traditional therapies that require ongoing administration.
What is the highest forecasted price for VERV Verve Therapeutics Inc.?
The highest price target for VERV is $32.00 from Whitney Ijem at Canaccord Genuity, which represents a 436.0% increase from the current price of $5.97.
What is the lowest forecasted price for VERV Verve Therapeutics Inc.?
The lowest price target for VERV is $15.00 from Luca Issi at RBC Capital, which represents a 151.3% increase from the current price of $5.97.
What is the overall VERV consensus from analysts for Verve Therapeutics Inc.?
The overall analyst consensus for VERV is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are VERV stock price projections?
Stock price projections, including those for Verve Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
